Juvenescence: Think aging up, rather than disease down
New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle.
Master Investor 2022: Our CEO, Dr. Greg Bailey, presents Juvenescence
The investment community is chasing a longer, healthier life like the rest of us.
The Simple Biotech Podcast: ‘Investing in the Longevity Industry: The Greatest Investment Opportunity in Human History’
What makes longevity one of the greatest investment opportunities in human history?
Juvenescence Chairman explains why investing in longevity has the potential to deliver significant financial, personal and humanitarian returns.
There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health
THE BUCK INSTITUTE, WHERE THE PROMISE OF AGING RESEARCH ISN’T LONGEVITY
The leaders of the Buck Institute for Research on Aging want you to know that they’re not going to make you immortal.
Longevity Technology: Equity investment in MDI Therapeutics by Juvenescence will develop novel serpin-based therapies
Longevity Technology reports on Juvenescence investment in the important work of MDI Therapeutics.
M2Bio Sciences Interview: Dr. Greg Bailey Goes Deep on Juvenescence, Longevity Biotech, and His Personal Story
Greg goes deep on Juvenescence, longevity biotech and his personal story.
Juvenescence Appoints Dr Richard Marshall CBE as CEO
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan.
Longevity Secrets of the Experts
Healthspan and longevity research has exploded in the past decade, and as scientists learn more about the biology of aging
What Is Metabolic Age and Why It Should Matter to You
Everyone ages — it’s one of the indisputable facts of life. From the moment we are born, each one of us starts a linear process of growth and maturation
Juvenescence’s Latest Venture, MDI Therapeutics, Inc., Targeting Fibrotic Disease
A biopharmaceutical company focused on treating aging and age-related disease
BBC Science Focus Magazine: An End To Aging?
The human suffering is huge, and in the next 30 years, the number of over-65-year-olds is projected to double to 1.5 billion.